Rooban Sivakumar

Mr. Rooban Sivakumar


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2024 in Metabolism Open
Verified
Journal Article
Open access
RSRooban Sivakumar
Rooban Sivakumar
KSK.A. Arul Senghor
K.A. Arul Senghor
VVV.M. Vinodhini
V.M. Vinodhini
JKJ.S. Kumar
J.S. Kumar
Adropin, a peptide discovered in 2008, has gained recognition as a key regulator of cardiovascular health and metabolic balance. Initially identified for its roles in energy balance, lipid metabolism, and glucose regulation, adropin has also been found to improve cardiovascular health by enhancing endothelial function, modulating lipid profiles, and reducing oxidative stress. These protective mechanisms suggest that adropin may be able to help prevent conditions such as atherosclerosis, hypertension, and other cardiovascular diseases. Research has established connections between adropin and cardiovascular risk factors, such as obesity, insulin resistance, and dyslipidemia, positioning it as a valuable biomarker for evaluating cardiovascular disease risk. New studies highlight adropin's diagnostic and prognostic significance, showing that higher levels are linked to better cardiovascular outcomes, while lower levels are associated with a higher risk of cardiovascular diseases. This review aims to summarize current knowledge on adropin, emphasizing its significance as a promising focus in the intersection of cardiovascular health and metabolic health. By summarizing the latest research findings, this review aims to offer insights into the potential applications of adropin in both clinical practice and research, leading to a deeper understanding of its role in maintaining cardiovascular and metabolic health.

17 August 2025 in Microplastics
Verified
Journal Article
Open access
PDF file
RSRooban Sivakumar
Rooban Sivakumar
AAArul Senghor Kadalangudi Aravaanan
Arul Senghor Kadalangudi Aravaanan
VMVinodhini Vellore Mohanakrishnan
Vinodhini Vellore Mohanakrishnan
JKJanardanan Subramonia Kumar
Janardanan Subramonia Kumar
Microplastics, synthetic polymer particles measuring less than 5 mm, have become a widespread environmental pollutant, raising concerns over their possible effects on human health. Growing evidence links MPs to vascular aging and cardiovascular disease beyond their ecological toxicity. Upon inhalation, ingestion, or skin contact, microplastics can traverse biological barriers, circulate systemically, and accumulate in vascular tissues. Experimental investigations indicate that MPs, especially polystyrene and polyethylene in nano- and micro-sized forms, induce oxidative stress, mitochondrial dysfunction, and chronic inflammation. These disruptions activate redox-sensitive signaling pathways, such as NF-κB and NLRP3 inflammasome, causing endothelial dysfunction, vascular smooth muscle modulation, and foam cell production, indicating early vascular aging. Animal models and in vitro studies have consistently shown endothelial activation, increased cytokine production, and changes in vascular tone after exposure to MPs. Initial human research has detected microplastics in blood, thrombi, and atherosclerotic plaques, which correlate with negative cardiovascular outcomes and systemic inflammation. Notably, recent research suggests that the gut microbiota and antioxidant systems may play a role in adaptive reactions, although these processes are still not fully understood. MP-induced vascular toxicity is covered in this interdisciplinary review, highlighting molecular pathways, experimental data, and translational gaps.

5 June 2025 in Drugs & Aging
Verified
Journal Article
Closed access
PDF file
RSRooban Sivakumar
Rooban Sivakumar
KSK. A. Arul Senghor
K. A. Arul Senghor
VVV. M. Vinodhini
V. M. Vinodhini
JKJanardhanan S. Kumar
Janardhanan S. Kumar

9 April 2026 in Diseases
Verified
Journal Article
Open access
PDF file
RSRooban Sivakumar
Rooban Sivakumar
AAArul Senghor Kadalangudi Aravaanan
Arul Senghor Kadalangudi Aravaanan
VMVinodhini Vellore Mohanakrishnan
Vinodhini Vellore Mohanakrishnan
JKJanardanan Subramonia Kumar
Janardanan Subramonia Kumar
Background: Early vascular aging (EVA) is a common complication of type 2 diabetes mellitus. Early identification is crucial in middle-aged individuals with T2DM, as vascular stiffness can occur gradually for years before cardiovascular disease. However, EVA is rarely considered in routine care. Adropin is a vasoprotective peptide that may counter-regulate endothelin-1 (ET-1). Therefore, this study aims to examine the association between circulating adropin, ET-1, oxLDL, MMP-2, VEGFA, and EVA. Methods: This observational study included 300 adults aged 25–55 years (150 T2DM; 150 age/sex-matched controls). ePWV was calculated from age and mean blood pressure. EVA was classified using a residual-based, age-specific ePWV threshold derived from controls. Associations were tested using correlation and logistic regression. ROC and decision curve analyses were performed to evaluate diagnostic performance and clinical utility. Results: EVA prevalence was 38.6% overall, occurring in 7.3% of controls and increasing across T2DM with good and poor glycemic control (56.1% and 80.95%, respectively, p < 0.001). Compared with normal vascular aging, EVA showed lower adropin and higher ET-1, oxLDL and MMP-2, with lower VEGFA (all p < 0.05). In fully adjusted models, adropin (OR 0.991 per pg/mL; p < 0.001) and ET-1 (OR 1.017 per pg/mL, p = 0.005) remained independently associated with EVA. A combined adropin + ET-1 predictor improved discrimination (AUC 0.901, 95% CI 0.868–0.934), at a predicted-probability cutoff of 0.607, 78.7% sensitivity and 87.0% specificity. Conclusions: In middle-aged T2DM, EVA was associated with lower adropin and higher ET-1 in T2DM. These findings support an association between these biomarkers and the EVA phenotype.

14 April 2025 in Iranian Journal of Public Health
Verified
Journal Article
Open access
PDF file
RSRooban Sivakumar
Rooban Sivakumar
AAArul Senghor Kadalangudi Aravaanan
Arul Senghor Kadalangudi Aravaanan
VMVinodhini Vellore Mohanakrishnan
Vinodhini Vellore Mohanakrishnan
JKJanardhanan Kumar
Janardhanan Kumar
Background: Adropin, a peptide hormone has role in various various physiological processes, including metabolic regulation and cardiovascular health. This systematic review aimed to synthesize findings from observational studies on the involvement of adropin in neurological disorders and cognitive performance. Methods: An extensive literature search was conducted across PubMed, Scopus, Web of Science, Embase, CORE, and Google Scholar using terms such as "adropin," "Neurological Disorders," "cognitive function," "Alzheimer's disease," "Parkinson's disease," "cognition," and "brain function." Studies published from 2020 to 2024 were selected and reviewed. The search and selection process adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Out of 127 screened articles, 5 met the inclusion criteria for this review. Results: The combined research findings suggest a consistent link between decreased adropin levels and a range of neurological disorders and cognitive impairments. In particular, reduced adropin levels were seen in individuals with dementia, cognitive impairment, bipolar disorder, Parkinson's disease, and multiple sclerosis. These findings highlight adropin's potential role in modulating neurological health and cognitive function. Conclusion: This systematic review underscores the importance of adropin in neurological health and its potential as a therapeutic agent. Based on the observed connections, adropin might serve as a new focus for treating neurological disorders, prompting the need for more research and trials.

1 January 2026 in Current Cardiology Reviews
Verified
Journal Article
Open access
PDF file
RSRooban Sivakumar
Rooban Sivakumar
AAArul Senghor Kadalangudi Aravaanan
Arul Senghor Kadalangudi Aravaanan
VMVinodhini Vellore Mohanakrishnan
Vinodhini Vellore Mohanakrishnan
JKJanardhanan Kumar
Janardhanan Kumar
Vascular aging profoundly affects the onset of cardiovascular diseases in the elderly, mostly as a result of mitochondrial dysfunction. This review examines the protective roles of mitochondrial- derived peptides such as humanin, MOTS-c, and small humanin-like peptides in mitigating vascular aging. These peptides, encoded by mitochondrial DNA, are crucial for regulating apoptosis, inflammation, and oxidative stress, which have a major role in vascular health. MDPs have significant prospects as therapeutic and biomarker possibilities for the early diagnosis and intervention of vascular aging. MDPs influence the functions of endothelial and vascular smooth muscle cells by modulating critical signaling pathways, including AMPK, mTOR, and sirtuins. These pathways are essential for facilitating cellular metabolism, enhancing stress resilience, and prolonging longevity. Moreover, MDPs are essential in mitochondrial bioenergetics and dynamics, vital for mitigating endothelial dysfunction and enhancing vascular resilience. Furthermore, MDPs contribute to immunological modulation and the regulation of inflammatory responses, underscoring their potential therapeutic applications in the treatment of age-related vascular disorders. This review analyzes the various functions of MDPs in vascular health and their therapeutic importance, advocating for more studies to optimize their clinical benefits. By understanding the comprehensive roles and mechanisms of these multifunctional peptides, we can better appreciate their capacity to prevent and treat vascular aging and associated cardiovascular disorders. Future research should aim to further elucidate their therapeutic effects and optimize their clinical applications.